Literature DB >> 19798093

In vivo dynamics of human cord blood-derived CD34(-) SCID-repopulating cells using intra-bone marrow injection.

T Kimura1, Y Matsuoka, M Murakami, T Kimura1, M Takahashi, T Nakamoto, K Yasuda, K Matsui, K Kobayashi, S Imai, H Asano, R Nakatsuka, Y Uemura, Y Sasaki, Y Sonoda.   

Abstract

The identification of human CD34-negative (CD34(-)) hematopoietic stem cells (HSCs) provides a new concept for the hierarchy in the human HSC compartment. This study investigated the long-term repopulating capacity and redistribution kinetics of human cord blood-derived CD34(-) severe combined immunodeficiency (SCID)-repopulating cells (SRCs) and compared them with those of CD34(+)CD38(+) and CD34(+)CD38(-) SRCs using the intra-bone marrow injection (IBMI) to clarify the characteristics of CD34(-) SRCs. On the basis of the limiting dilution analyses data, estimated numbers of CD34(+)CD38(+), CD34(+)CD38(-), and CD34(-) SRCs were transplanted to NOD/SCID mice by IBMI. The human cell repopulation at the site of injection and the other bones were serially investigated. Interestingly, CD34(+)CD38(+), CD34(+)CD38(-), and CD34(-) SRCs began to migrate to other bones 2 and 5 weeks after the transplantation, respectively. Accordingly, the initiation of migration seemed to differ between the CD34(+) and CD34(-) SRCs. In addition, CD34(+)CD38(+) SRCs only sustained a short-term repopulation. However, both CD34(+)CD38(-) and CD34(-) SRCs had longer-term repopulation capacity. Taken together, these findings showed that CD34(-) SRCs show different in vivo kinetics, thus suggesting that the identified CD34(-) SRCs are a distinct class of primitive HSCs in comparison to the CD34(+)CD38(+) and CD34(+)CD38(-) SRCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19798093     DOI: 10.1038/leu.2009.206

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  CD34-negative hematopoietic stem cells show distinct expression profiles of homing molecules that limit engraftment in mice and sheep.

Authors:  Tomoyuki Abe; Yoshikazu Matsuoka; Yoshikazu Nagao; Yoshiaki Sonoda; Yutaka Hanazono
Journal:  Int J Hematol       Date:  2017-07-07       Impact factor: 2.490

2.  The number of CD34+CD133+ hematopoietic stem cells residing in umbilical cord blood (UCB) units is not correlated with the numbers of total nucleated cells and CD34+ cells: a possible new indicator for quality evaluation of UCB units.

Authors:  Yoshikazu Matsuoka; Fumiaki Nakamura; Kazuo Hatanaka; Tatsuya Fujioka; Satoshi Otani; Takafumi Kimura; Yoshihiro Fujimura; Hiroaki Asano; Yoshiaki Sonoda
Journal:  Int J Hematol       Date:  2018-07-25       Impact factor: 2.490

Review 3.  Cancer stem cells and cancer therapy.

Authors:  Sara Soltanian; Maryam M Matin
Journal:  Tumour Biol       Date:  2011-02-12

4.  CD34 Antigen and the MPL Receptor Expression Defines a Novel Class of Human Cord Blood-Derived Primitive Hematopoietic Stem Cells.

Authors:  Yoshikazu Matsuoka; Masaya Takahashi; Keisuke Sumide; Hiroshi Kawamura; Ryusuke Nakatsuka; Tatsuya Fujioka; Yoshiaki Sonoda
Journal:  Cell Transplant       Date:  2016-11-30       Impact factor: 4.064

5.  A revised road map for the commitment of human cord blood CD34-negative hematopoietic stem cells.

Authors:  Keisuke Sumide; Yoshikazu Matsuoka; Hiroshi Kawamura; Ryusuke Nakatsuka; Tatsuya Fujioka; Hiroaki Asano; Yoshihiro Takihara; Yoshiaki Sonoda
Journal:  Nat Commun       Date:  2018-06-06       Impact factor: 14.919

6.  Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment.

Authors:  Sydney Felker; Archana Shrestha; Jeff Bailey; Devin M Pillis; Dylan Siniard; Punam Malik
Journal:  JCI Insight       Date:  2022-05-09

7.  CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells.

Authors:  M Takahashi; Y Matsuoka; K Sumide; R Nakatsuka; T Fujioka; H Kohno; Y Sasaki; K Matsui; H Asano; K Kaneko; Y Sonoda
Journal:  Leukemia       Date:  2013-11-05       Impact factor: 11.528

8.  Human cord blood-derived primitive CD34-negative hematopoietic stem cells (HSCs) are myeloid-biased long-term repopulating HSCs.

Authors:  Y Matsuoka; K Sumide; H Kawamura; R Nakatsuka; T Fujioka; Y Sasaki; Y Sonoda
Journal:  Blood Cancer J       Date:  2015-03-13       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.